The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
The Neurotrophins and Their Role in Alzheimers Disease
Open accessAbstract
Besides being essential for correct development of the vertebrate nervous system the neurotrophins also play a vital role in adult neuron survival, maintenance and regeneration. In addition they are implicated in the pathogenesis of certain neurodegenerative diseases, and may even provide a therapeutic solution for some. In particular there have been a number of studies on the involvement of nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) in the development of Alzheimer's disease. This disease is of growing concern as longevity increases worldwide, with little treatment available at the moment to alleviate the condition. Memory loss is one of the earliest symptoms associated with Alzheimer's disease. The brain regions first affected by pathology include the hippocampus, and also the entorhinal cortex and basal cholinergic nuclei which project to the hippocampus; importantly, all these areas are required for memory formation. Both NGF and BDNF are affected early in the disease and this is thought to initiate a cascade of events which exacerbates pathology and leads to the symptoms of dementia. This review briefly describes the pathology, symptoms and molecular processes associated with Alzheimer's disease; it discusses the involvement of the neurotrophins, particularly NGF and BDNF, and their receptors, with changes in BDNF considered particularly in the light of its importance in synaptic plasticity. In addition, the possibilities of neurotrophin-based therapeutics are evaluated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 2×
“The ‘Amyloid Hypothesis’ [30, 31]) proposes that increased A formation, deposition or decreased clearance is sufficient to produce all the neuropathology and associated symptoms leading to dementia in Alzheimer’s disease.”
BackgroundThe cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · cited 3×
“Subjects carrying this polymorphism have been shown to be less successful in tests of episodic short-term memory, and functional MRI (magnetic resonance imaging) shows differences in glucose utilization [133, 134].”
BackgroundVassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · cited 1×
“In the late 1970s and early 1980s there were reports of considerable deficits in the function of the cholinergic system in post-mortem tissue, including reductions in the activity of choline acetyltransferase, the enzyme responsible for the synthesis of acetylcholine [8-10].”
BackgroundThe molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Mesulam, M. ‐., Mufson, E. J., Levey, A. I., & Wainer, B. H. (1983) · Journal of Comparative Neurology · doi:10.1002/cne.902140206 · Cited by 1,962
Neurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944 · cited 15×
“Later TrkA mRNA and protein was shown to be present in neurons of the ChBF [55-56]; with over 90% TrkA colocalisation with p75NTR, but with only TrkA not p75NTR expressed in the striatal neurons [56].”
BackgroundInfluentialAlzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Regulation of Cell Survival by Secreted Proneurotrophins
Lee, R., Kermani, P., Teng, K. K., & Hempstead, B. L. (2001) · Science · doi:10.1126/science.1065057 · Cited by 1,670
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 1×
“Less than three weeks after injection there was a fivefold increase in tangle formation, in the area of the amygdala from where neurons project to the injection sites [40].”
BackgroundHippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor.
Korte, M., Carroll, P., Wolf, E., Brem, G., Thoenen, H., & Bonhoeffer, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8856 · Cited by 1,426 · cited 1×
“Removal or reduction of BDNF, using BDNF antisense [110, 111], anti-BDNF antibodies [112] or in BDNF heterozygous knockout mice [113-115] produces a marked deficit in L-LTP.”
MethodThe trk Proto-Oncogene Product: a Signal Transducing Receptor for Nerve Growth Factor
Kaplan, D. R., Hempstead, B. L., Martin-Zanca, D., Chao, M. V., & Parada, L. F. (1991) · Science · doi:10.1126/science.1850549 · Cited by 1,379
Decreased serum brain-derived neurotrophic factor levels in major depressed patients
Karege, F., Perret, G., Bondolfi, G., Schwald, M., Bertschy, G., & Aubry, J.-M. (2002) · Psychiatry Research · doi:10.1016/s0165-1781(02)00005-7 · Cited by 1,232 · cited 1×
“Reductions in serum BDNF levels have been reported in patients with depressive disorders [136], whereas increased BDNF levels are seen following antidepressant treatment [137].”
BackgroundShimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., Nakazato, M., Watanabe, H., Shinoda, N., Okada, S.-I., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00181-1 · Cited by 1,151 · cited 1×
“Reductions in serum BDNF levels have been reported in patients with depressive disorders [136], whereas increased BDNF levels are seen following antidepressant treatment [137].”
BackgroundFigurov, A., Pozzo-Miller, L. D., Olafsson, P., Wang, T., & Lu, B. (1996) · Nature · doi:10.1038/381706a0 · Cited by 1,106
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050
Hariri, A. R., Goldberg, T. E., Mattay, V. S., Kolachana, B. S., Callicott, J. H., Egan, M. F., & Weinberger, D. R. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-17-06690.2003 · Cited by 1,045
Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034 · cited 2×
“The authors point out that this approach could be scaled up to deliver BDNF to the human entorhinal cortex, and that the “potency of BDNF seen in the preclinical models provides a rationale for exploring clinical translation” [178].”
BackgroundRequirement for BDNF in activity-dependent survival of cortical neurons
Ghosh, A., Carnahan, J., & Greenberg, M. E. (1994) · Science · doi:10.1126/science.7907431 · Cited by 989 · cited 1×
“BDNF is highly expressed and widely distributed throughout the central nervous system especially in the hippocampus and cerebral cortex [92-93] and is important in the survival and function of hippocampal, cortical, cholinergic and dopaminergic neurons [94-97].”
BackgroundBrunoni, A. R., Lopes, M., & Fregni, F. (2008) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009309 · Cited by 972
Sortilin is essential for proNGF-induced neuronal cell death
Nykjaer, A., Lee, R., Teng, K. K., Jansen, P., Madsen, P., Nielsen, M. S., Jacobsen, C., Kliemannel, M., Schwarz, E., Willnow, T. E., et al. (2004) · Nature · doi:10.1038/nature02319 · Cited by 962 · cited 2×
“The receptor sortilin has been shown to be a necessary p75NTR co-receptor for proNGF-mediated apoptosis [47].”
BackgroundBrain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Pezawas, L., Verchinski, B. A., Mattay, V. S., Callicott, J. H., Kolachana, B. S., Straub, R. E., Egan, M. F., Meyer-Lindenberg, A., & Weinberger, D. R. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2680-04.2004 · Cited by 890
Activation of p75NTR by proBDNF facilitates hippocampal long-term depression
Woo, N. H., Teng, H. K., Siao, C.-J., Chiaruttini, C., Pang, P. T., Milner, T. A., Hempstead, B. L., & Lu, B. (2005) · Nature Neuroscience · doi:10.1038/nn1510 · Cited by 815 · cited 4×
“There are contradictory studies as to the extent of processing of proBDNF to BDNF, whether this occurs intracellularly or extracellularly, by which protease, and whether proBDNF can remain unprocessed long enough to have a role in LTD [125-127].”
BackgroundInfluentialEssential Role for TrkB Receptors in Hippocampus-Mediated Learning
Minichiello, L., Korte, M., Wolfer, D., Kühn, R., Unsicker, K., Cestari, V., Rossi-Arnaud, C., Lipp, H.-P., Bonhoeffer, T., & Klein, R. (1999) · Neuron · doi:10.1016/s0896-6273(00)80853-3 · Cited by 799 · cited 1×
“Neuroserpin levels however, were found to be significantly elevated, whilst endogenous plasminogen activator inhibitor-1 and protease nexin-1 levels were unchanged.”
BackgroundPeng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03135.x · Cited by 691
DeKosky, S. T., Ikonomovic, M. D., Styren, S. D., Beckett, L., Wisniewski, S., Bennett, D. A., Cochran, E. J., Kordower, J. H., & Mufson, E. J. (2002) · Annals of Neurology · doi:10.1002/ana.10069 · Cited by 686 · cited 4×
“ProNGF levels have now been shown to progressively increase during the disease process from MCI to end stage, and are associated with poorer performance on cognitive tests [74, 75].”
BackgroundInfluentialWilcock, G. K., & Esiri, M. M. (1982) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(82)90155-1 · Cited by 608
Salehi, A., Delcroix, J.-D., Belichenko, P. V., Zhan, K., Wu, C., Valletta, J. S., Takimoto-Kimura, R., Kleschevnikov, A. M., Sambamurti, K., Chung, P. P., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.05.022 · Cited by 543 · cited 1×
“Further studies in this mouse model related this to increased APP protein in the ChBF neurons [67].”
BackgroundNeurotrophins and Time: Different Roles for TrkB Signaling in Hippocampal Long-Term Potentiation
Kang, H., Welcher, A. A., Shelton, D., & Schuman, E. M. (1997) · Neuron · doi:10.1016/s0896-6273(00)80378-5 · Cited by 481
Learning deficit in BDNF mutant mice.
Linnarsson, S., Björklund, A., & Ernfors, P. (1997) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1997.tb01687.x · Cited by 471
Gene Transfer and Molecular Cloning of the Human NGF Receptor
Chao, M. V., Bothwell, M. A., Ross, A. H., Koprowski, H., Lanahan, A. A., Buck, C. R., & Sehgal, A. (1986) · Science · doi:10.1126/science.3008331 · Cited by 449 · cited 1×
“NGF interacts with both the panneurotrophin receptor p75NTR [45] and the high-affinity NGF-specific receptor TrkA on the surface of the cholinergic neurons [46-47].”
BackgroundGratacòs, M., González, J. R., Mercader, J. M., de Cid, R., Urretavizcaya, M., & Estivill, X. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.025 · Cited by 428
Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., Nehama, D., Rajadas, J., & Longo, F. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41356 · Cited by 406 · cited 2×
“In addition small molecule mimetics of NGF or BDNF have also been suggested as Alzheimer therapeutics [180, 181].”
BackgroundKorte, M., Griesbeck, O., Gravel, C., Carroll, P., Staiger, V, Thoenen, H., & Bonhoeffer, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12547 · Cited by 351 · cited 1×
“L-LTP can be rescued in these mice by viral transfer of BDNF [117], even when all new protein synthesis is blocked [114], suggesting that it may be the only protein required to maintain L-LTP.”
BackgroundYoshii, A., & Constantine-Paton, M. (2007) · Nature Neuroscience · doi:10.1038/nn1903 · Cited by 345 · cited 1×
“BDNF then binds to TrkB localized at pre- or postsynaptic glutamatergic synapses [108]; at postsynaptic sites, TrkB associates with NMDA receptors and PSD95 (post synaptic density 95) [109].”
BackgroundCooper, J. D., Salehi, A., Delcroix, J.-D., Howe, C. L., Belichenko, P. V., Chua-Couzens, J., Kilbridge, J. F., Carlson, E. J., Epstein, C. J., & Mobley, W. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181219298 · Cited by 336 · cited 1×
“In a mouse model of Down’s syndrome (Trisomy 16), retrograde transport of radiolabelled NGF from the hippocampus to the septum was markedly reduced [66].”
BackgroundRegional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimerʼs disease
Narisawa-Saito, M., Wakabayashi, K., Tsuji, S., Takahashi, H., & Nawa, H. (1996) · NeuroReport · doi:10.1097/00001756-199611250-00024 · Cited by 226 · cited 1×
“BDNF mRNA levels in Alzheimer’s disease hippocampus [142] and parietal cortex [143] and decreased protein levels of BDNF in entorhinal cortex, hippocampus, temporal, frontal and parietal cortex [144-147].”
BackgroundBliss, T. V. P., & Lømo, T. (1973) · The Journal of Physiology · doi:10.1113/jphysiol.1973.sp010273 · Cited by 135
Barker, P. A. (2009) · Nature Neuroscience · doi:10.1038/nn0209-105 · Cited by 110
Delineating the Mechanism of Alzheimer’s Disease Aβ Peptide Neurotoxicity
Cappai, R., & Barnham, K. J. (2008) · Neurochemical Research · doi:10.1007/s11064-007-9469-8 · Cited by 108
Zou, Y.-F., Ye, D.-Q., Feng, X.-L., Su, H., Pan, F.-M., & Liao, F.-F. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.12.005 · Cited by 104
Cited by
The role of CREB and BDNF in neurobiology and treatment of Alzheimer's disease
Amidfar, M., de Oliveira, J., Kucharska, E., Budni, J., & Kim, Y.-K. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118020 · Cited by 410
Raefsky, S. M., & Mattson, M. P. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.11.045 · Cited by 257
CREB expression mediates amyloid β-induced basal BDNF downregulation
Rosa, E., & Fahnestock, M. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.014 · Cited by 138
ApoE4 and Aβ Oligomers Reduce BDNF Expression via HDAC Nuclear Translocation
Sen, A., Nelson, T. J., & Alkon, D. L. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0260-15.2015 · Cited by 133
Garcez, M. L., Mina, F., Bellettini-Santos, T., Carneiro, F. G., Luz, A. P., Schiavo, G. L., Andrighetti, M. S., Scheid, M. G., Bolfe, R. P., & Budni, J. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.03.010 · Cited by 102
Metadata
- Authors
- J. Allen, S., J. Watson, J., & Dawbarn, D.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-12-01
- Volume
- 9
- Issue
- 4
- Pages
- 559-573
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W2004665203
- Cited by
- 177
- References
- 46
- FWCI
- 6.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.